Advertisement

Dementia in Parkinson's disease

  • Hasmet A. Hanagasi
    Correspondence
    Corresponding author at: Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Çapa, 34390 Istanbul, Turkey.
    Affiliations
    Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Istanbul, Turkey
    Search for articles by this author
  • Zeynep Tufekcioglu
    Affiliations
    Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Istanbul, Turkey
    Search for articles by this author
  • Murat Emre
    Affiliations
    Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Istanbul, Turkey
    Search for articles by this author
Published:January 05, 2017DOI:https://doi.org/10.1016/j.jns.2017.01.012

      Highlights

      • Parkinson's disease dementia (PDD) is a common and age-associated non-motor manifestation in patients with Parkinson’s disease.
      • Pathologies associated with PD-D include Lewy body-type degeneration, cellular loss in subcortical nuclei and cortical Alzheimer-type pathology.
      • Cholinesterase inhibitors such as rivastigmine and donepezil exert beneficial effects with moderate effect size.

      Abstract

      Dementia can occur in a substantial number of patients with Parkinson's disease with a point prevalence close to 30%. The cognitive profile is characterized by predominant deficits in executive, visuospatial functions, attention and memory. Behavioral symptoms are frequent such as apathy, visual hallucinations and delusions. The most prominent associated pathology is Lewy body-type and biochemical deficit is cholinergic. Placebo-controlled randomized trials with cholinesterase inhibitors demonstrated modest but significant benefits in cognition, behavioral symptoms and global functions.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Aarsland D.
        • Zaccai J.
        • Brayne C.
        A systematic review of prevalence studies of dementia in Parkinson's disease.
        Mov. Disord. Oct 2005; 20: 1255-1263
        • Williams-Gray C.H.
        • Mason S.L.
        • Evans J.R.
        • et al.
        The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort.
        J. Neurol. Neurosurg. Psychiatry. 2013; 84: 1258-1264https://doi.org/10.1136/jnnp-2013-305277
        • Santangelo G.
        • Vitale C.
        • Picillo M.
        • Moccia M.
        • Cuoco S.
        • Longo K.
        • et al.
        Mild Cognitive Impairment in newly diagnosed Parkinson's disease: a longitudinal prospective study.
        Parkinsonism Relat. Disord. Oct 2015; 21 (Epub 2015 Aug 21): 1219-1226https://doi.org/10.1016/j.parkreldis.2015.08.024
        • Pigott K.
        • Rick J.
        • Xie S.X.
        • Hurtig H.
        • Chen-Plotkin A.
        • Duda J.E.
        • et al.
        Longitudinal study of normal cognition in Parkinson disease.
        Neurology. Oct 13 2015; 85 (Epub 2015 Sep 11): 1276-1282https://doi.org/10.1212/WNL.0000000000002001
        • Hely M.A.
        • Morris J.G.
        • Reid W.G.
        • Trafficante R.
        Sydney Multicenter Study of Parkinson's disease: non-l-dopa-responsive problems dominate at 15 years.
        Mov. Disord. Feb 2005; 20 (PubMed PMID: 15551331): 190-199
        • Hely M.A.
        • Reid W.G.
        • Adena M.A.
        • Halliday G.M.
        • Morris J.G.
        The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.
        Mov. Disord. Apr 30 2008; 23 (PubMed PMID: 18307261): 837-844https://doi.org/10.1002/mds.21956
        • Levy G.
        • Schupf N.
        • Tang M.-X.
        • Cote L.J.
        • Louis E.D.
        • Mejia H.
        • et al.
        Combined effect of age and severity on the risk of dementia in Parkinson's disease.
        Ann. Neurol. Jun 2002; 51: 722-729
        • Marion M.-H.
        • Qurashi M.
        • Marshall G.
        • Foster O.
        Is REM sleep behaviour disorder (RBD) a risk factor of dementia in idiopathic Parkinson's disease?.
        J. Neurol. Feb 2008; 255: 192-196
        • Anang J.B.
        • Gagnon J.F.
        • Bertrand J.A.
        • Romenets S.R.
        • Latreille V.
        • Panisset M.
        • et al.
        Predictors of dementia in Parkinson disease: a prospective cohort study.
        Neurology. Sep 30 2014; 83 (Epub 2014 Aug 29): 1253-1260https://doi.org/10.1212/WNL.0000000000000842
        • Williams-Gray C.H.
        • Evans J.R.
        • Goris A.
        • Foltynie T.
        • Ban M.
        • Robbins T.W.
        • et al.
        The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort.
        Brain. Nov 2009; 132: 2958-2969
        • Lee S.J.
        • Kim J.S.
        • Yoo J.Y.
        • Song I.U.
        • Kim B.S.
        • Jung S.L.
        • et al.
        Influence of white matter hyperintensities on the cognition of patients with Parkinson disease.
        Alzheimer Dis. Assoc. Disord. Sep 2010; 24: 227-233
        • Ham J.H.
        • Lee J.J.
        • Sunwoo M.K.
        • Hong J.Y.
        • Sohn Y.H.
        • Lee P.H.
        Effect of olfactory impairment and white matter hyperintensities on cognition in Parkinson's disease.
        Parkinsonism Relat. Disord. Mar 2016; 24 (Epub 2015 Dec 31): 95-99https://doi.org/10.1016/j.parkreldis.2015.12.017
        • Lee S.J.
        • Lee D.G.
        The cross-sectional and longitudinal relationships between white matter hyperintensities and dementia in patients with Parkinson's disease: a retrospective analysis of 132 patients in a single center.
        Arch. Gerontol. Geriatr. Jan–Feb 2016; 62 (Epub 2015 Oct 26): 133-137https://doi.org/10.1016/j.archger.2015.10.006
        • Kandiah N.
        • Zainal N.H.
        • Narasimhalu K.
        • Chander R.J.
        • Ng A.
        • Mak E.
        • et al.
        Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease.
        Parkinsonism Relat. Disord. Nov 2014; 20 (Epub 2014 Sep 16): 1203-1208https://doi.org/10.1016/j.parkreldis.2014.08.024
        • Pilotto A.
        • Turrone R.
        • Liepelt-Scarfone I.
        • Bianchi M.
        • Poli L.
        • Borroni B.
        • et al.
        Vascular risk factors and cognition in Parkinson's disease.
        J. Alzheimers Dis. 2016; 51: 563-570https://doi.org/10.3233/JAD-150610
        • Malek N.
        • Lawton M.A.
        • Swallow D.M.
        • Grosset K.A.
        • Marrinan S.L.
        • Bajaj N.
        • PRoBaND Clinical Consortium
        • et al.
        Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease.
        Mov. Disord. Jun 21 2016; https://doi.org/10.1002/mds.26698
        • Mata I.F.
        • Leverenz J.B.
        • Weintraub D.
        • Trojanowski J.Q.
        • Hurtig H.I.
        • Van Deerlin V.M.
        • et al.
        APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.
        JAMA Neurol. Nov 2014; 71: 1405-1412https://doi.org/10.1001/jamaneurol.2014.1455
        • Huang X.
        • Chen P.C.
        • Poole C.
        APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease.
        Neurology. Jun 22 2004; 62: 2198-2202
        • Goris A.
        • Williams-Gray C.H.
        • Clark G.R.
        • Foltynie T.
        • Lewis S.J.G.
        • Brown J.
        • et al.
        Tau and alpha-synuclein in susceptibility to, and dementia in Parkinson's disease.
        Ann. Neurol. Aug 2007; 62: 145-153
        • Healy D.G.
        • Abou-Sleiman P.M.
        • Lees A.J.
        • Casas J.P.
        • Quinn N.
        • Bhatia K.
        • et al.
        Tau gene and Parkinson's disease: a case-control study and meta-analysis.
        J. Neurol. Neurosurg. Psychiatry. Jul 2004; 75: 962-965
        • Winder-Rhodes S.E.
        • Evans J.R.
        • Ban M.
        • Mason S.L.
        • Williams-Gray C.H.
        • Foltynie T.
        • et al.
        Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort.
        Brain. Feb 2013; 136: 392-399https://doi.org/10.1093/brain/aws318
        • Zokaei N.
        • McNeill A.
        • Proukakis C.
        • Beavan M.
        • Jarman P.
        • Korlipara P.
        • et al.
        Visual short-term memory deficits associated with GBA mutation and Parkinson's disease.
        Brain. Aug 2014; 137 (Epub 2014 Jun 11): 2303-2311https://doi.org/10.1093/brain/awu143
        • Davis M.Y.
        • Johnson C.O.
        • Leverenz J.B.
        • Weintraub D.
        • Trojanowski J.Q.
        • Chen-Plotkin A.
        • et al.
        Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease.
        JAMA Neurol. Aug 29 2016; https://doi.org/10.1001/jamaneurol.2016.2245
        • Farrer M.
        • Kachergus J.
        • Forno L.
        • Lincoln S.
        • Wang D.-S.
        • Hulihan M.
        • et al.
        Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications.
        Ann. Neurol. Feb 2004; 55: 174-179
        • Sironi F.
        • Trotta L.
        • Antonini A.
        • Zini M.
        • Ciccone R.
        • Della Mina E.
        • et al.
        alpha-Synuclein multiplication analysis in Italian familial Parkinson disease.
        Parkinsonism Relat. Disord. Mar 2010; 16: 228-231
        • Alcalay R.N.
        • Caccappolo E.
        • Mejia-Santana H.
        • Tang M.X.
        • Rosado L.
        • Orbe Reilly M.
        • et al.
        Cognitive and motor function in long-duration PARKIN-associated Parkinson disease.
        JAMA Neurol. Jan 2014; 71: 62-67https://doi.org/10.1001/jamaneurol.2013.4498
        • Petrova M.
        • Raycheva M.
        • Traykov L.
        Cognitive profile of the earliest stage of dementia in Parkinson's disease.
        Am. J. Alzheimers Dis. Other Demen. Dec 2012; 27 (Epub 2012 Sep 19): 614-619https://doi.org/10.1177/1533317512460562
        • Marras C.
        • Armstrong M.J.
        • Meaney C.A.
        • Fox S.
        • Rothberg B.
        • Reginold W.
        • et al.
        Measuring mild cognitive impairment in patients with Parkinson's disease.
        Mov. Disord. May 2013; 28 (Epub 2013 Mar 20): 626-633https://doi.org/10.1002/mds.25426
        • Broeders M.
        • de Bie R.M.
        • Velseboer D.C.
        • Speelman J.D.
        • Muslimovic D.
        • Schmand B.
        Evolution of mild cognitive impairment in Parkinson disease.
        Neurology. Jul 23 2013; 81 (Epub 2013 Jun 21): 346-352https://doi.org/10.1212/WNL.0b013e31829c5c86
        • Goldman J.G.
        • Holden S.
        • Bernard B.
        • Ouyang B.
        • Goetz C.G.
        • Stebbins G.T.
        Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease.
        Mov. Disord. Dec 2013; 28 (Epub 2013 Oct 9): 1972-1979https://doi.org/10.1002/mds.25655
        • Pfeiffer H.C.
        • Løkkegaard A.
        • Zoetmulder M.
        • Friberg L.
        • Werdelin L.
        Cognitive impairment in early-stage non-demented Parkinson's disease patients.
        Acta Neurol. Scand. May 2014; 129 (Epub 2013 Oct 11): 307-318https://doi.org/10.1111/ane.12189
        • Yarnall A.J.
        • Breen D.P.
        • Duncan G.W.
        • Khoo T.K.
        • Coleman S.Y.
        • Firbank M.J.
        • et al.
        Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study.
        Neurology. Jan 28 2014; 82 (Epub 2013 Dec 20): 308-316https://doi.org/10.1212/WNL.0000000000000066
        • Stefanova E.
        • Žiropadja L.
        • Stojković T.
        • Stanković I.
        • Tomić A.
        • Ječmenica-Lukić M.
        • et al.
        Mild cognitive impairment in early Parkinson's disease using the Movement Disorder Society Task Force Criteria: cross-sectional study in Hoehn and Yahr stage 1.
        Dement. Geriatr. Cogn. Disord. 2015; 40 (Epub 2015 Jul 28): 199-209https://doi.org/10.1159/000433421
        • Johnson D.K.
        • Langford Z.
        • Garnier-Villarreal M.
        • Morris J.C.
        • Galvin J.E.
        Onset of mild cognitive impairment in Parkinson disease.
        Alzheimer Dis. Assoc. Disord. Apr–Jun 2016; 30: 127-133https://doi.org/10.1097/WAD.0000000000000088
        • Noe E.
        • Marder K.
        • Bell K.L.
        • Jacobs D.M.
        • Manly J.J.
        • Stern Y.
        Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia.
        Mov. Disord. Jan 2004; 19 (PubMed PMID: 14743362): 60-67
        • Weintraub D.
        • Moberg P.J.
        • Culbertson W.C.
        • Duda J.E.
        • Stern M.B.
        Evidence for impaired encoding and retrieval memory profiles in Parkinson disease.
        Cogn. Behav. Neurol. Dec 2004; 17: 195-200
        • Mosimann U.P.
        • Mather G.
        • Wesnes K.A.
        • O'Brien J.T.
        • Burn D.J.
        • McKeith I.G.
        Visual perception in Parkinson disease dementia and dementia with Lewy bodies.
        Neurology. Dec 14 2004; 63: 2091-2096
        • Aarsland D.
        • Brønnick K.
        • Ehrt U.
        • De Deyn P.P.
        • Tekin S.
        • Emre M.
        • et al.
        Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress.
        J. Neurol. Neurosurg. Psychiatry. Jan 2007; 78: 36-42
        • Pagonabarraga J.
        • Llebaria G.
        • García-Sánchez C.
        • Pascual-Sedano B.
        • Gironell A.
        • Kulisevsky J.
        A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia.
        Mov. Disord. Feb 15 2008; 23: 443-448
        • McDonald C.
        • Newton J.L.
        • Burn D.J.
        Orthostatic hypotension and cognitive impairment in Parkinson's disease: causation or association?.
        Mov. Disord. Jul 2016; 31 (Review. PubMed PMID: 27091624): 937-946https://doi.org/10.1002/mds.26632
        • Allan L.M.
        • Ballard C.G.
        • Allen J.
        • Murray A.
        • Davidson A.W.
        • McKeith I.G.
        • et al.
        Autonomic dysfunction in dementia.
        J. Neurol. Neurosurg. Psychiatry. Jul 2007; 78: 671-677
        • Emre M.
        What causes mental dysfunction in Parkinson's disease?.
        Mov. Disord. Sep 2003; 18: S63-S71
        • Horvath J.
        • Herrmann F.R.
        • Burkhard P.R.
        • Bouras C.
        • Kövari E.
        Neuropathology of dementia in a large cohort of patients with Parkinson's disease.
        Parkinsonism Relat. Disord. Oct 2013; 19 (discussion 864) (Epub 2013 Jun 6): 864-868
        • Irwin D.J.
        • White M.T.
        • Toledo J.B.
        • Xie S.X.
        • Robinson J.L.
        • Van Deerlin V.
        • et al.
        Neuropathologic substrates of Parkinson disease dementia.
        Ann. Neurol. Oct 2012; 72 (Epub 2012 Oct 4): 587-598https://doi.org/10.1002/ana.23659
        • Schneider J.A.
        • Arvanitakis Z.
        • Yu L.
        • Boyle P.A.
        • Leurgans S.E.
        • Bennett D.A.
        Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies.
        Brain. Oct 2012; 135: 3005-3014https://doi.org/10.1093/brain/aws234
        • Liu A.K.
        • Chang R.C.
        • Pearce R.K.
        • Gentleman S.M.
        Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease.
        Acta Neuropathol. Apr 2015; 129 (Epub 2015 Jan 30. Review): 527-540https://doi.org/10.1007/s00401-015-1392-5
        • Jellinger K.A.
        Morphological substrates of mental dysfunction in Lewy body disease: an update.
        J. Neural Transm. Suppl. 2000; 59: 185-212
        • Jellinger K.A.
        Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway.
        Mol. Chem. Neuropathol. Jun 1991; 14: 153-197
        • Apostolova L.G.
        • Beyer M.
        • Green A.E.
        • Hwang K.S.
        • Morra J.H.
        • Chou Y.-Y.
        • et al.
        Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia.
        Mov. Disord. Apr 30 2010; 25: 687-688
        • Borroni B.
        • Premi E.
        • Formenti A.
        • Turrone R.
        • Alberici A.
        • Cottini E.
        • et al.
        Structural and functional imaging study in dementia with Lewy bodies and Parkinson's disease dementia.
        Parkinsonism Relat. Disord. Sep 2015; 21 (Epub 2015 Jun 16): 1049-1055https://doi.org/10.1016/j.parkreldis.2015.06.013
        • Seibert T.M.
        • Murphy E.A.
        • Kaestner E.J.
        • Brewer J.B.
        Interregional correlations in Parkinson disease and Parkinson-related dementia with resting functional MR imaging.
        Radiology. Apr 2012; 263: 226-234
        • Peraza L.R.
        • Colloby S.J.
        • Firbank M.J.
        • Greasy G.S.
        • McKeith I.G.
        • Kaiser M.
        • et al.
        Resting state in Parkinson's disease dementia and dementia with Lewy bodies: commonalities and differences.
        Int. J. Geriatr. Psychiatry. Nov 2015; 30 (Epub 2015 Aug 13): 1135-1146https://doi.org/10.1002/gps.4342
        • Duncan G.W.
        • Firbank M.J.
        • Yarnall A.J.
        • Khoo T.K.
        • Brooks D.J.
        • Barker R.A.
        • et al.
        Gray and white matter imaging: a biomarker for cognitive impairment in early Parkinson's disease?.
        Mov. Disord. Jan 2016; 31 (PubMed PMID: 26202802): 103-110https://doi.org/10.1002/mds.26312
        • Pavese N.
        PET studies in Parkinson's disease motor and cognitive dysfunction.
        Parkinsonism Relat. Disord. Jan 2012; 18: S96-S99
        • Hilker R.
        • Thomas A.V.
        • Klein J.C.
        • Weisenbach S.
        • Kalbe E.
        • Burghaus L.
        • et al.
        Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways.
        Neurology. Dec 13 2005; 65: 1716-1722
        • Maetzler W.
        • Reimold M.
        • Liepelt I.
        • Solbach C.
        • Leyhe T.
        • Schweitzer K.
        • et al.
        [11C]PIB binding in Parkinson's disease dementia.
        NeuroImage. Feb 1 2008; 39: 1027-1033
        • Edison P.
        • Rowe C.C.
        • Rinne J.O.
        • Ng S.
        • Ahmed I.
        • Kemppainen N.
        • et al.
        Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography.
        J. Neurol. Neurosurg. Psychiatry. Dec 2008; 79: 1331-1338
        • Stav A.L.
        • Aarsland D.
        • Johansen K.K.
        • Hessen E.
        • Auning E.
        • Fladby T.
        Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
        Parkinsonism Relat. Disord. Jul 2015; 21 (Epub 2015 May 2): 758-764https://doi.org/10.1016/j.parkreldis.2015.04.027
        • Bäckström D.C.
        • Eriksson Domellöf M.
        • Linder J.
        • Olsson B.
        • Öhrfelt A.
        • Trupp M.
        • et al.
        Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease.
        JAMA Neurol. Oct 2015; 72: 1175-1182https://doi.org/10.1001/jamaneurol.2015.1449
        • Skillbäck T.
        • Farahmand B.Y.
        • Rosén C.
        • Mattsson N.
        • Nägga K.
        • Kilander L.
        • et al.
        Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
        Brain. Sep 2015; 138 (Epub 2015 Jun 30): 2716-2731https://doi.org/10.1093/brain/awv181
        • Stewart T.
        • Liu C.
        • Ginghina C.
        • Cain K.C.
        • Auinger P.
        • Cholerton B.
        • Shi M.
        • Zhang J.
        • Parkinson Study Group DATATOP Investigators
        Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.
        Am. J. Pathol. Apr 2014; 184 (Epub 2014 Mar 11. PubMed PMID: 24625392; PubMed Central PMCID: PMC3969999): 966-975https://doi.org/10.1016/j.ajpath.2013.12.007
        • Latreille V.
        • Carrier J.
        • Gaudet-Fex B.
        • Rodrigues-Brazète J.
        • Panisset M.
        • Chouinard S.
        • et al.
        Electroencephalographic prodromal markers of dementia across conscious states in Parkinson's disease.
        Brain. Apr 2016; 139 (Epub 2016 Feb 16): 1189-1199https://doi.org/10.1093/brain/aww018
        • Emre M.
        • Aarsland D.
        • Brown R.
        • Burn D.J.
        • Duyckaerts C.
        • Mizuno Y.
        • et al.
        Clinical diagnostic criteria for dementia associated with Parkinson's disease.
        Mov. Disord. Sep 15 2007; 22 (quiz 1837): 1689-1707
        • Dubois B.
        • Burn D.
        • Goetz C.
        • Aarsland D.
        • Brown R.G.
        • Broe G.A.
        • et al.
        Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force.
        Mov. Disord. Dec 2007; 22: 2314-2324
        • Litvan I.
        • Goldman J.G.
        • Tröster A.I.
        • Schmand B.A.
        • Weintraub D.
        • Petersen R.C.
        • et al.
        Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.
        Mov. Disord. Mar 2012; 27: 349-356
        • McKeith I.G.
        Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop.
        J. Alzheimers Dis. 2006; 9: 417-423
        • Aarsland D.
        • Londos E.
        • Ballard C.
        Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity.
        Int. Psychogeriatr. Apr 2009; 21: 216-219
        • Lippa C.F.
        • Duda J.E.
        • Grossman M.
        • Hurtig H.I.
        • Aarsland D.
        • Boeve B.F.
        • et al.
        DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.
        Neurology. Mar 13 2007; 68: 812-819
        • McKeith I.G.
        • Mosimann U.P.
        Dementia with Lewy bodies and Parkinson's disease.
        Parkinsonism Relat. Disord. May 2004; 10: S15-S18
        • McKeith I.
        Dementia with Lewy bodies and Parkinson's disease with dementia: where two worlds collide.
        Pract. Neurol. Nov 2007; 7: 374-382
        • Hepp D.H.
        • Vergoossen D.L.
        • Huisman E.
        • Lemstra A.W.
        • Netherlands Brain Bank
        • Berendse H.W.
        • et al.
        Distribution and load of amyloid-β pathology in Parkinson disease and dementia with Lewy bodies.
        J. Neuropathol. Exp. Neurol. Aug 11 2016; (pii: nlw070)
        • Donaghy P.
        • Thomas A.J.
        • O'Brien J.T.
        Amiloid PET imaging in Lewy body disorders.
        Am. J. Geriatr. Psychiatry. Jan 2015; 23 (Epub 2013 Jul 3): 23-37https://doi.org/10.1016/j.jagp.2013.03.001
        • Beyer M.K.
        • Larsen J.P.
        • Aarsland D.
        Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies.
        Neurology. Aug 21 2007; 69 (PubMed PMID: 17709706): 747-754
        • McKeith I.G.
        • Dickson D.W.
        • Lowe J.
        • Emre M.
        • O'Brien J.T.
        • Feldman H.
        • et al.
        Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.
        Neurology. Dec 27 2005; 65: 1863-1872
        • Mamikonyan E.
        • Xie S.X.
        • Melvin E.
        • Weintraub D.
        Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.
        Mov. Disord. Jun 2015; 30 (Epub 2015 Apr 25): 912-918https://doi.org/10.1002/mds.26236
        • Grace J.
        • Amick M.M.
        • Friedman J.H.
        A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease.
        J. Neurol. Neurosurg. Psychiatry. Jan 2009; 80: 18-23
        • Emre M.
        • Aarsland D.
        • Albanese A.
        • Byrne E.J.
        • Deuschl G.
        • De Deyn P.P.
        • et al.
        Rivastigmine for dementia associated with Parkinson's disease.
        N. Engl. J. Med. Dec 9 2004; 351: 2509-2518
        • Poewe W.
        • Wolters E.
        • Emre M.
        • Onofrj M.
        • Hsu C.
        • Tekin S.
        • et al.
        Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
        Mov. Disord. Apr 2006; 21: 456-461
        • Wesnes K.A.
        • McKeith I.
        • Edgar C.
        • Emre M.
        • Lane R.
        Benefits of rivastigmine on attention in dementia associated with Parkinson disease.
        Neurology. Nov 22 2005; 65: 1654-1656
        • Wang H.F.
        • Yu J.T.
        • Tang S.W.
        • Jiang T.
        • Tan C.C.
        • Meng X.F.
        • et al.
        Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis.
        J. Neurol. Neurosurg. Psychiatry. Feb 2015; 86 (Epub 2014 May 14. Review): 135-143https://doi.org/10.1136/jnnp-2014-307659
        • Aarsland D.
        • Ballard C.
        • Walker Z.
        • Bostrom F.
        • Alves G.
        • Kossakowski K.
        • et al.
        Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
        Lancet Neurol. Jul 2009; 8: 613-618
        • Emre M.
        • Tsolaki M.
        • Bonuccelli U.
        • Destée A.
        • Tolosa E.
        • Kutzelnigg A.
        • et al.
        Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
        Lancet Neurol. Oct 2010; 9: 969-977
        • Hughes A.J.
        • Daniel S.E.
        • Kilford L.
        • Lees A.J.
        Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.
        J. Neurol. Neurosurg. Psychiatry. Mar 1992; 55 (PubMed PMID: 1564476; PubMed Central PMCID: PMC1014720): 181-184